| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 22.8 | 21.5 |
| Gross profit | 17.4 | 16.1 |
| Profit before tax | -8.2 | -13.8 |
| Net income | -8.4 | -14.0 |
| EPS (diluted, $ a share) | $-0.19 | $-0.34 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +6.2% |
|---|---|
| Gross margin | 76.2% |
| Operating margin | -32.8% |
10-Q filed with the SEC, NASDAQ: LUNG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pulmonx Corp: key numbers
- Share price
- $2.80Close, Nov 16
- Market cap
- $122M
- Shares outstanding
- 43.55MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pulmonx Corp
All →Pulmonx Financial Results
Pulmonx reported Q3 2026 worldwide revenue of $22.8 million, a 6% increase year-over-year, driven by 7% growth in the U.S. market. The company significantly reduced its net loss by 40% to $8.4 million and its Adjusted EBITDA loss by 57% through cost realignment efforts while maintaining a strong gross margin of 76%.
- Term
- Q3 2026
“We are very pleased to have returned to year-over-year revenue growth in the third quarter. We continue to execute on our commercial strategy, advance our clinical initiatives, and deliver the operating leverage we expected.”
Glen French, President and Chief Executive Officer